The U.S. Food and Drug Administration (FDA) has given Boehringer Ingelheim’s antidote to its problematic anticoagulant drug Pradaxa a fast-track review, FiercePhrama reports. According to the company, this will make Pradaxa the first “next generation” anticoagulant to receive an FDA-approved antidote.
Last year, the German drug manufacturer Boehringer Ingelheim agreed to pay $650 million to settle roughly 4,000 Pradaxa lawsuits in state and federal courts. Plaintiffs ...
continue reading...
